Cortney Caudill - 09 Mar 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: SVP, CHIEF OPERATING OFFICER
Signature: /s/ James R. Oehler, Attorney-in-Fact
Issuer symbol: HALO
Transactions as of: 09 Mar 2026
Net transactions value: -$1,955,160
Form type: 4
Filing time: 10 Mar 2026, 19:18:55 UTC
Previous filing: 24 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO	/s/ James R. Oehler, Attorney-in-Fact	10 Mar 2026	0002090209

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Options Exercise		+20,000	+139%	$33.51^*	34,366	09 Mar 2026	Direct
transaction	HALO	Common Stock	Sale	$1,212,743	-17,900	-52%	$67.75	16,466	09 Mar 2026	Direct	F1
transaction	HALO	Common Stock	Sale	$143,329	-2,100	-13%	$68.25	14,366	09 Mar 2026	Direct	F2
transaction	HALO	Common Stock	Options Exercise		+1,546	+11%	$33.51^*	15,912	10 Mar 2026	Direct
transaction	HALO	Common Stock	Sale	$599,087	-8,857	-56%	$67.64	7,055	10 Mar 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Options Exercise		-20,000	-22%	$33.51^*	69,224	09 Mar 2026	Common Stock	20,000	$33.51	Direct	F4
transaction	HALO	Option to Purchase Common Stock	Options Exercise		-1,546	-2.2%	$33.51^*	67,678	10 Mar 2026	Common Stock	1,546	$33.51	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2	Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3	Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4	Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023.